Pacira BioSciences Inc. Reports Positive Two-Year Efficacy Data for PCRX-201 in Knee Osteoarthritis

BRISBANE, Calif., April 28, 2025 — Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain management and regenerative health solutions, announced significant findings from its latest study on PCRX-201 (enekinragene inzadenovec). The study demonstrated sustained improvements in knee pain, stiffness, and function for up to two years following a single local administration in patients with mild to severe osteoarthritis of the knee.

The data, presented at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, highlighted clinically meaningful improvements across all structural severity subgroups, including those with advanced disease. This marks a significant milestone for Pacira BioSciences in its commitment to providing innovative, non-opioid pain therapies.

Key Highlights:

  • Sustained Efficacy: PCRX-201 showed two years of clinically meaningful improvements in pain, stiffness, and function.
  • Broad Applicability: The therapy was effective across all structural severity subgroups, including patients with advanced osteoarthritis.
  • Single Administration: The improvements were observed following a single local administration, emphasizing the potential for reduced treatment burden.

Pacira BioSciences, a pharmaceutical company operating in the health care sector, continues to focus on non-opioid pain management solutions. The company, which went public on the Nasdaq stock exchange on February 3, 2011, serves customers primarily in the United States.

Market Context:

  • Close Price (April 24, 2025): $25.72
  • 52-Week High (May 16, 2024): $31.67
  • 52-Week Low (August 12, 2024): $11.16

The announcement of these positive results is expected to bolster investor confidence in Pacira BioSciences’ innovative approach to pain management. The company remains dedicated to transforming patient care through its cutting-edge therapies.

For more information, visit Pacira BioSciences’ website .